Literature DB >> 25342978

Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects.

Jiwon Oh1, Paul W O'Connor2.   

Abstract

A number of novel oral agents are now approved for use in relapsing multiple sclerosis (MS). Among these agents, teriflunomide has shown promise with respect to clinical efficacy and safety in relapsing MS patients. In this review we aim to clarify the role of teriflunomide in the context of current and emerging MS treatment options by summarizing relevant points on the use of teriflunomide in MS, with a discussion of teriflunomide's pharmacologic properties, pivotal clinical trials, and safety and tolerability.

Entities:  

Keywords:  clinical trials; multiple sclerosis; review; teriflunomide

Year:  2014        PMID： 25342978      PMCID： PMC4206621          DOI： 10.1177/1756285614546855

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN： 1756-2856            Impact factor:   6.570


  29 in total

1.  A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner.

Authors:  L C Hamilton; I Vojnovic; T D Warner
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

Review 2.  Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature.

Authors:  K Warnatz; H H Peter; M Schumacher; L Wiese; A Prasse; F Petschner; P Vaith; B Volk; S M Weiner
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

3.  Pregnancy outcome in women exposed to leflunomide before or during pregnancy.

Authors:  M Cassina; D L Johnson; L K Robinson; S R Braddock; R Xu; J L Jimenez; N Mirrasoul; E Salas; Y J Luo; K L Jones; C D Chambers
Journal:  Arthritis Rheum       Date:  2012-07

4.  The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms.

Authors:  R T Elder; X Xu; J W Williams; H Gong; A Finnegan; A S Chong
Journal:  J Immunol       Date:  1997-07-01       Impact factor: 5.422

5.  Leflunomide-associated progressive multifocal leukoencephalopathy.

Authors:  Megan Rahmlow; Elizabeth A Shuster; Jacob Dominik; H Gordon Deen; Dennis W Dickson; Allen J Aksamit; Hector A Robles; William D Freeman
Journal:  Arch Neurol       Date:  2008-11

Review 6.  Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.

Authors:  M L Herrmann; R Schleyerbach; B J Kirschbaum
Journal:  Immunopharmacology       Date:  2000-05

7.  Suppression of experimental autoimmune neuritis by leflunomide.

Authors:  T Korn; K Toyka; H P Hartung; S Jung
Journal:  Brain       Date:  2001-09       Impact factor: 13.501

8.  Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

Authors:  Paul O'Connor; Jerry S Wolinsky; Christian Confavreux; Giancarlo Comi; Ludwig Kappos; Tomas P Olsson; Hadj Benzerdjeb; Philippe Truffinet; Lin Wang; Aaron Miller; Mark S Freedman
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

9.  Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide.

Authors:  T Mattar; K Kochhar; R Bartlett; E G Bremer; A Finnegan
Journal:  FEBS Lett       Date:  1993-11-15       Impact factor: 4.124

10.  Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors.

Authors:  L D Fairbanks; M Bofill; K Ruckemann; H A Simmonds
Journal:  J Biol Chem       Date:  1995-12-15       Impact factor: 5.157
View more
  9 in total

Review 1.  Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2.

Authors:  Aryan Rafiee Zadeh; Keyvan Ghadimi; Akram Ataei; Mozhde Askari; Neda Sheikhinia; Nooshin Tavoosi; Masih Falahatian
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2019-08-15

2.  Teriflunomide Modulates Vascular Permeability and Microglial Activation after Experimental Traumatic Brain Injury.

Authors:  Karthik S Prabhakara; Daniel J Kota; Gregory H Jones; Amit K Srivastava; Charles S Cox; Scott D Olson
Journal:  Mol Ther       Date:  2018-07-05       Impact factor: 11.454

Review 3.  Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients.

Authors:  Elizabeth A Mills; Yang Mao-Draayer
Journal:  Mult Scler       Date:  2018-05-18       Impact factor: 6.312

Review 4.  Clinical Pharmacokinetic Monitoring of Leflunomide in Renal Transplant Recipients with BK Virus Reactivation: A Review of the Literature.

Authors:  Joan C Y Ng; Marianna Leung; Alissa J Wright; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2017-09       Impact factor: 5.577

Review 5.  Benefit-Risk of Therapies for Relapsing-Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-Analysis.

Authors:  Diogo Mendes; Carlos Alves; Francisco Batel-Marques
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 6.497

Review 6.  Targeting the Redox Landscape in Cancer Therapy.

Authors:  Dilip Narayanan; Sana Ma; Dennis Özcelik
Journal:  Cancers (Basel)       Date:  2020-06-27       Impact factor: 6.639

Review 7.  Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?

Authors:  Georgios K Vasileiadis; Efthymios Dardiotis; Athanasios Mavropoulos; Zisis Tsouris; Vana Tsimourtou; Dimitrios P Bogdanos; Lazaros I Sakkas; Georgios M Hadjigeorgiou
Journal:  Auto Immun Highlights       Date:  2018-11-10

Review 8.  Safety of Newer Disease Modifying Therapies in Multiple Sclerosis.

Authors:  Georges Jalkh; Rachelle Abi Nahed; Gabrielle Macaron; Mary Rensel
Journal:  Vaccines (Basel)       Date:  2020-12-26

9.  Long-term evolution of multiple sclerosis disability in the treatment era.

Authors:  Bruce A C Cree; Pierre-Antoine Gourraud; Jorge R Oksenberg; Carolyn Bevan; Elizabeth Crabtree-Hartman; Jeffrey M Gelfand; Douglas S Goodin; Jennifer Graves; Ari J Green; Ellen Mowry; Darin T Okuda; Daniel Pelletier; H-Christian von Büdingen; Scott S Zamvil; Alisha Agrawal; Stacy Caillier; Caroline Ciocca; Refujia Gomez; Rachel Kanner; Robin Lincoln; Antoine Lizee; Pamela Qualley; Adam Santaniello; Leena Suleiman; Monica Bucci; Valentina Panara; Nico Papinutto; William A Stern; Alyssa H Zhu; Gary R Cutter; Sergio Baranzini; Roland G Henry; Stephen L Hauser
Journal:  Ann Neurol       Date:  2016-08-13       Impact factor: 10.422
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.